Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertapenem vs Piperacillin/Tazobactam in Complicated Intra-Abdominal Infections
NCT00389987Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2001
- Primary completion
- May 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ertapenem in Intra-abdominal infection (IAI) (2 arms), sponsored by Merck & Co. Primary endpoint: Clinical response in microbiologically evaluable patients at the 2-weeks post-treatment Early Follow-up Assessment. Started Sep 2001; status: completed.
02
Drugs
ertapenem
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT00389987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389987.